Zacks Investment Research downgraded shares of Natera, Inc. (NASDAQ:NTRA) from a buy rating to a hold rating in a research report released on Thursday morning.
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
A number of other research analysts have also commented on the company. Robert W. Baird reiterated a buy rating on shares of Natera in a research report on Tuesday, October 24th. Morgan Stanley reiterated an overweight rating and issued a $16.00 price objective (up from $13.00) on shares of Natera in a research report on Friday, October 6th. Cowen and Company reiterated a buy rating and issued a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. BidaskClub upgraded Natera from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Finally, ValuEngine upgraded Natera from a strong sell rating to a sell rating in a research report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Natera currently has an average rating of Hold and an average target price of $16.20.
Shares of Natera (NTRA) traded up 0.18% during mid-day trading on Thursday, hitting $11.14. The stock had a trading volume of 141,349 shares. Natera has a 12-month low of $7.35 and a 12-month high of $14.76. The stock’s market cap is $592.90 million. The firm’s 50-day moving average price is $12.89 and its 200 day moving average price is $12.89.
Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.52). The firm had revenue of $53.60 million for the quarter, compared to analyst estimates of $50.57 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company earned ($0.46) EPS. Equities analysts forecast that Natera will post ($2.08) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/10/29/natera-inc-ntra-downgraded-by-zacks-investment-research.html.
In other Natera news, insider Jonathan Sheena sold 120,000 shares of Natera stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the transaction, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 12.57% of the company’s stock.
A number of hedge funds have recently bought and sold shares of NTRA. Virtu KCG Holdings LLC bought a new position in Natera during the second quarter worth about $126,000. American International Group Inc. lifted its holdings in Natera by 7.1% during the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after acquiring an additional 1,068 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Natera by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after acquiring an additional 194 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in Natera during the second quarter worth about $151,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Natera by 45.3% during the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after acquiring an additional 5,417 shares in the last quarter. Hedge funds and other institutional investors own 59.74% of the company’s stock.
Natera Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Natera Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natera Inc. and related companies.